Get the Stockscreener App
6.3191
84.94%
-35.28
Tvardi Therapeutics Inc stock is traded at $6.3191, with a volume of 2.37M.
It is down -84.94% in the last 24 hours and down -81.51% over the past month.
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.
See More
Previous Close:
$41.60
Open:
$6.2
24h Volume:
2.37M
Relative Volume:
56.78
Market Cap:
$59.08M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-84.41%
1M Performance:
-81.51%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$5.65
$6.50
1-Week Range:
$5.65
$43.65
52-Week Range:
$5.65
$43.65
Tvardi Therapeutics Inc Stock (TVRD) Company Profile
Name
Tvardi Therapeutics Inc
Sector
Industry
Phone
(713) 489-8654
Address
3 SUGAR CREEK CTR. BLVD., SUGAR LAND
Compare TVRD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TVRD
Tvardi Therapeutics Inc
|
6.30 | 390.10M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.82 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
459.48 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.00 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.73 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
325.17 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Tvardi Therapeutics Inc Stock (TVRD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-14-25 | Initiated | Raymond James | Outperform |
| Jul-11-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-12-25 | Initiated | Piper Sandler | Overweight |
| May-21-25 | Initiated | Oppenheimer | Outperform |
| May-15-25 | Initiated | BTIG Research | Buy |
| Jun-13-24 | Downgrade | Canaccord Genuity | Buy → Hold |
| Jun-13-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-13-24 | Downgrade | Needham | Buy → Hold |
| Jun-13-24 | Downgrade | Stifel | Buy → Hold |
| Mar-08-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Mar-08-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-01-21 | Resumed | Canaccord Genuity | Buy |
| Aug-03-21 | Initiated | JP Morgan | Neutral |
| Apr-21-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-12-19 | Reiterated | H.C. Wainwright | Buy |
| May-29-19 | Reiterated | Laidlaw | Buy |
| Feb-06-19 | Resumed | Jefferies | Buy |
| Jan-15-19 | Initiated | BofA/Merrill | Neutral |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-13-18 | Initiated | Jefferies | Buy |
| Aug-08-18 | Reiterated | Stifel | Buy |
| Jun-28-18 | Reiterated | H.C. Wainwright | Buy |
| Mar-12-18 | Resumed | H.C. Wainwright | Buy |
| Feb-12-18 | Upgrade | Janney | Neutral → Buy |
| Jan-19-18 | Initiated | Seaport Global Securities | Buy |
View All
Tvardi Therapeutics Inc Stock (TVRD) Latest News
Can swing trading help recover from Tvardi Therapeutics Inc. losses2025 Market Overview & AI Enhanced Execution Alerts - newser.com
Will Tvardi Therapeutics Inc. benefit from macro trendsQuarterly Portfolio Summary & Daily Oversold Stock Bounce Ideas - newser.com
Using RSI to spot recovery in Tvardi Therapeutics Inc.July 2025 Intraday Action & Community Consensus Trade Alerts - newser.com
Using data models to predict Tvardi Therapeutics Inc. stock movement2025 Earnings Surprises & Community Consensus Trade Alerts - newser.com
Tvardi Therapeutics, Inc. (NASDAQ:TVRD) most popular amongst retail investors who own 57% of the shares, institutions hold 26% - Yahoo Finance
Tvardi Therapeutics Inc. stock volume spike explainedJuly 2025 Pullbacks & Weekly Market Pulse Updates - newser.com
Published on: 2025-10-10 08:50:26 - newser.com
Best data tools to analyze Tvardi Therapeutics Inc. stockJuly 2025 Analyst Calls & High Accuracy Swing Entry Alerts - newser.com
Tvardi Therapeutics Inc. stock daily chart insightsJuly 2025 Pullbacks & Weekly Top Gainers Alerts - newser.com
Is Tvardi Therapeutics Inc 69C a good long term investmentStock Rotation Strategies & Get Tomorrow’s Winners Today With AI - earlytimes.in
Published on: 2025-10-06 07:23:43 - newser.com
Order flow analysis tools used on Tvardi Therapeutics Inc.July 2025 Short Interest & Weekly Stock Performance Updates - newser.com
Is it time to cut losses on Tvardi Therapeutics Inc.Trade Exit Summary & Entry Point Confirmation Alerts - newser.com
Will Tvardi Therapeutics Inc. (69C) stock beat value stocks2025 Market Trends & Weekly Watchlist for Hot Stocks - newser.com
Why analysts remain bullish on Tvardi Therapeutics Inc. stockAnalyst Downgrade & Risk Controlled Daily Plans - newser.com
Will Tvardi Therapeutics Inc. price bounce be sustainableBull Run & Entry Point Confirmation Alerts - newser.com
Is Tvardi Therapeutics Inc. stock cheap at current valuationJuly 2025 Trends & Weekly Setup with ROI Potential - newser.com
What dividend safety score for Tvardi Therapeutics Inc. stockEntry Point & Verified Momentum Watchlists - newser.com
What the charts say about Tvardi Therapeutics Inc. today2025 Volume Leaders & Intraday High Probability Setup Alerts - newser.com
Tvardi Therapeutics, Inc. (NASDAQ:TVRD) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Published on: 2025-09-30 05:12:21 - newser.com
Published on: 2025-09-30 03:36:47 - newser.com
Tvardi Therapeutics Inc 69C Stock Analysis and ForecastStop Loss Placement Tips & Predict Price Movements With AI Precision - earlytimes.in
Is Tvardi Therapeutics Inc a good long term investmentDividend Growth Stocks & Start Learning With Our Courses - earlytimes.in
Published on: 2025-09-30 00:49:11 - newser.com
Tvardi Therapeutics Inc Stock (TVRD) Financials Data
There is no financial data for Tvardi Therapeutics Inc (TVRD). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Tvardi Therapeutics Inc Stock (TVRD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Terrillion Scott | SEC'Y; CHIEF COMPLIANCE & G.C. |
Feb 28 '25 |
Sale |
4.76 |
163 |
776 |
7,190 |
| Posner Christopher | PRESIDENT AND CEO |
Feb 04 '25 |
Sale |
4.72 |
372 |
1,756 |
13,692 |
| Posner Christopher | PRESIDENT AND CEO |
Nov 04 '24 |
Sale |
0.29 |
3,668 |
1,064 |
168,768 |
2.20%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):